Literature DB >> 25055290

FDG PET/CT in the management of nasopharyngeal carcinoma.

Aravind Mohandas1, Charles Marcus, Hyunseok Kang, Minh-Tam Truong, Rathan M Subramaniam.   

Abstract

OBJECTIVE: FDG PET/CT has a growing role in the diagnosis and management of nasopharyngeal carcinoma (NPC). FDG PET has greater efficacy for N and M staging than other modalities, which enables the treating oncologists to select the appropriate mode of treatment. FDG PET/CT helps in radiation therapy planning, provides valuable prognostic information, and is useful in the assessment of therapy response and in follow-up to detect recurrences.
CONCLUSION: FDG PET/CT is a valuable imaging test in the management of NPC.

Entities:  

Keywords:  PET/CT; nasopharyngeal cancer; patient outcome; radiation therapy planning

Mesh：

Substances：

Year:  2014        PMID： 25055290     DOI： 10.2214/AJR.13.12420

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN： 0361-803X            Impact factor:   3.959


  12 in total

1.  Prognostic value of 18F-fluorodeoxyglucose PET parameters and inflammation in patients with nasopharyngeal carcinoma.

Authors:  Liting Zhong; Chunming Li; Yunyan Ren; Dehua Wu
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

2.  Value of 18F-FDG heterogeneity for discerning metastatic from benign lymph nodes in nasopharyngeal carcinoma patients with suspected recurrence.

Authors:  Seung Hwan Moon; Young Seok Cho; Young-Ik Son; Yong Chan Ahn; Myung-Ju Ahn; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Br J Radiol       Date:  2016-09-21       Impact factor: 3.039

3.  Pretreatment 18F-FDG uptake heterogeneity can predict treatment outcome of carbon ion radiotherapy in patients with locally recurrent nasopharyngeal carcinoma.

Authors:  Guang Ma; Bingxin Gu; Jiyi Hu; Lin Kong; Jiangang Zhang; Zili Li; Yangbo Xue; Jiade Lu; Junning Cao; Jingyi Cheng; Yingjian Zhang; Shaoli Song; Zhongyi Yang
Journal:  Ann Nucl Med       Date:  2021-04-28       Impact factor: 2.668

4.  Comparison of rigid and deformable image registration for nasopharyngeal carcinoma radiotherapy planning with diagnostic position PET/CT.

Authors:  Yudai Kai; Hidetaka Arimura; Ryo Toya; Tetsuo Saito; Tomohiko Matsuyama; Yoshiyuki Fukugawa; Shinya Shiraishi; Yoshinobu Shimohigashi; Masato Maruyama; Natsuo Oya
Journal:  Jpn J Radiol       Date:  2019-12-13       Impact factor: 2.374

Review 5.  Prognostic value of pretreatment 18F-FDG PET-CT for nasopharyngeal carcinoma patients.

Authors:  Yecai Huang; Mei Feng; Qiao He; Jun Yin; Peng Xu; Qinghua Jiang; Jinyi Lang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

6.  Nasopharyngeal carcinoma presenting as an inconspicuous primary lesion with extensive cavernous sinus involvement and temporal lobe extension: a case report and review of literature.

Authors:  Courtney Pollard; Shane M Mesko; Lawrence E Ginsberg; Merrill S Kies; Shaan M Raza; Shirley Y Su; Sam Tung; Jack Phan
Journal:  Clin Case Rep       Date:  2017-09-05

7.  (18)F-FDG Uptake Characteristics in Differentiating Benign from Malignant Nasopharyngeal Lesions in Children.

Authors:  Chao Ma; Renjian Zou; Yanlei Huo; Suyun Chen; Shaoyan Wang; Shuqi Wu; Zhiyi Ye; Zhenyu Wu; Feng Fang; Hui Wang
Journal:  Biomed Res Int       Date:  2015-10-20       Impact factor: 3.411

Review 8.  Emerging radiotherapy technologies and trends in nasopharyngeal cancer.

Authors:  Michelle Tseng; Francis Ho; Yiat Horng Leong; Lea Choung Wong; Ivan Wk Tham; Timothy Cheo; Anne Wm Lee
Journal:  Cancer Commun (Lond)       Date:  2020-08-03

9.  Diagnostic value of diffusion-weighted magnetic resonance imaging for local and skull base recurrence of nasopharyngeal carcinoma after radiotherapy.

Authors:  Chen Wang; Lidong Liu; Shaolv Lai; Danke Su; Younan Liu; Guanqiao Jin; Xuna Zhu; Ningbin Luo
Journal:  Medicine (Baltimore)       Date:  2018-08       Impact factor: 1.817

10.  High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy.

Authors:  Veysel Haksoyler; Erkan Topkan
Journal:  Ther Clin Risk Manag       Date:  2021-07-05       Impact factor: 2.423
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.